MX2009013272A - Formas amorfas estabilzadas de mesilato de imatinib. - Google Patents

Formas amorfas estabilzadas de mesilato de imatinib.

Info

Publication number
MX2009013272A
MX2009013272A MX2009013272A MX2009013272A MX2009013272A MX 2009013272 A MX2009013272 A MX 2009013272A MX 2009013272 A MX2009013272 A MX 2009013272A MX 2009013272 A MX2009013272 A MX 2009013272A MX 2009013272 A MX2009013272 A MX 2009013272A
Authority
MX
Mexico
Prior art keywords
imatinib mesylate
stabilized amorphous
amorphous forms
pharmaceutical compositions
amorphous form
Prior art date
Application number
MX2009013272A
Other languages
English (en)
Inventor
Oskar Kalb
Michael Mutz
Wolfgang Wirth
Jay Parthiban Lakshman
Elisabete Goncalves
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229765&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009013272(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009013272A publication Critical patent/MX2009013272A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a la forma amorfa estabilizada de la sal de adición de ácido metansulfónico de 4-(4-metilpiperazin-1-ilmeti l)-N-[4-metil-3-(4-(piridin-3-il)-pirimidin-2-ilamino)-fenil]-ben zamida, composiciones farmacéuticas tales como cápsulas o tabletas que contienen esta forma, el uso de dicha forma en métodos de diagnóstico o, preferiblemente, para el tratamiento terapéutico de animales de sangre caliente, especialmente seres humanos, y al uso de principio de formulación estabilizando la forma amorfa de mesilato de Imatinib como un intermediario para la preparación de composiciones farmacéuticas.
MX2009013272A 2007-06-07 2008-06-05 Formas amorfas estabilzadas de mesilato de imatinib. MX2009013272A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07109816A EP2000139A1 (en) 2007-06-07 2007-06-07 Stabilized amorphous forms of imatinib mesylate
US97419707P 2007-09-21 2007-09-21
PCT/US2008/065838 WO2008154262A1 (en) 2007-06-07 2008-06-05 Stabilized amorphous forms of imatinib mesylate

Publications (1)

Publication Number Publication Date
MX2009013272A true MX2009013272A (es) 2010-01-25

Family

ID=38229765

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013272A MX2009013272A (es) 2007-06-07 2008-06-05 Formas amorfas estabilzadas de mesilato de imatinib.

Country Status (27)

Country Link
US (4) US20100178336A1 (es)
EP (2) EP2000139A1 (es)
JP (2) JP5380440B2 (es)
KR (2) KR101267782B1 (es)
CN (2) CN104910134A (es)
AR (1) AR067328A1 (es)
AU (1) AU2008262059B2 (es)
BR (1) BRPI0812442A2 (es)
CA (1) CA2687741A1 (es)
CL (1) CL2008001658A1 (es)
CO (1) CO6241118A2 (es)
CY (1) CY1113178T1 (es)
DK (1) DK2305263T3 (es)
ES (1) ES2391625T3 (es)
HK (1) HK1150764A1 (es)
IL (2) IL202157A0 (es)
MX (1) MX2009013272A (es)
MY (1) MY148878A (es)
NZ (3) NZ598428A (es)
PL (1) PL2305263T3 (es)
PT (1) PT2305263E (es)
RU (1) RU2489149C2 (es)
SG (1) SG182175A1 (es)
SI (1) SI2305263T1 (es)
UY (1) UY31125A1 (es)
WO (1) WO2008154262A1 (es)
ZA (2) ZA200907961B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101041203B1 (ko) * 2007-09-25 2011-06-13 테바 파마슈티컬 인더스트리즈 리미티드 안정한 이매티닙 조성물
CZ20098A3 (cs) * 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
WO2012080703A1 (en) * 2010-12-15 2012-06-21 Cipla Limited Pharmaceutical composition comprising imatinib
WO2013077815A1 (en) 2011-11-24 2013-05-30 Ak Farma İlaç Sanayi Ve Ticaret A.Ş. Imatinib solid dosage forms reconstituted just before use
KR101386697B1 (ko) 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
US9439903B2 (en) 2012-10-25 2016-09-13 Cadila Healthcare Limited Process for the preparation of amorphous imatinib mesylate
CN103784411B (zh) * 2012-11-01 2016-03-23 齐鲁制药(海南)有限公司 一种盐酸厄洛替尼药用组合物及其制备方法
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
WO2015110949A1 (en) 2014-01-22 2015-07-30 Novartis Ag Imatinib as cholesterol decreasing agent
US20210046096A1 (en) * 2018-02-13 2021-02-18 Sandoz Ag Pharmaceutical Composition of Brigatinib
CN109044977A (zh) * 2018-10-26 2018-12-21 武汉工程大学 一种乐伐替尼固体分散体及其制备方法和制剂
EP4052713A1 (en) * 2019-11-01 2022-09-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical composition comprising quinazoline derivative or salt thereof
WO2022150483A1 (en) * 2021-01-06 2022-07-14 Incarda Therapeutics, Inc. Inhalable imatinib formulation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
RU2173172C2 (ru) * 1997-05-05 2001-09-10 Сайдекс Инк. Твердые фармацевтические препараты, содержащие физическую смесь сульфоалкилового эфира циклодекстрина и терапевтического агента
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
ATE400252T1 (de) * 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
WO2002087588A1 (fr) * 2001-04-26 2002-11-07 Meiji Seika Kaisha, Ltd. Composition de cefditoren pivoxil amorphe et procede de fabrication correspondant
TW200810743A (en) * 2002-03-22 2008-03-01 Novartis Ag Combination of organic compounds
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
US7300938B2 (en) * 2003-06-02 2007-11-27 Hetero Drugs Limited Polymorphs of imatinib mesylate
KR101370580B1 (ko) * 2004-06-08 2014-03-06 버텍스 파마슈티칼스 인코포레이티드 약학 조성물
US7329495B2 (en) * 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
FR2873693B1 (fr) * 2004-07-29 2006-09-15 Sanofi Synthelabo Derives d'amino-tropane, leur preparation et leur application en therapeutique
ES2306216T3 (es) * 2004-08-27 2008-11-01 Bayer Pharmaceuticals Corporation Composiciones farmaceuticas en forma de dispersiones solidas para el tratamiento de cancer.
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
US20080274192A1 (en) * 2005-05-19 2008-11-06 Pfizer Inc. Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor
EA015102B1 (ru) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Препараты наночастиц мезилата иматиниба
US8067421B2 (en) * 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
MX2009002336A (es) * 2006-09-01 2009-03-20 Teva Pharma Composiciones de imatinib.
MX2009009659A (es) * 2007-03-12 2009-09-22 Reddys Lab Ltd Dr Mesilato de imatinib.
US20080234286A1 (en) * 2007-03-20 2008-09-25 Chemagis Ltd. Stable amorphous imatinib mesylate and production process therefor

Also Published As

Publication number Publication date
WO2008154262A1 (en) 2008-12-18
NZ581176A (en) 2012-10-26
PL2305263T3 (pl) 2012-12-31
IL237160A0 (en) 2015-03-31
IL202157A0 (en) 2010-06-16
ZA200900796B (en) 2010-07-28
SG182175A1 (en) 2012-07-30
DK2305263T3 (da) 2012-10-22
CL2008001658A1 (es) 2009-02-20
KR101454086B1 (ko) 2014-10-27
SI2305263T1 (sl) 2012-10-30
EP2305263B1 (en) 2012-09-19
CN101678023A (zh) 2010-03-24
CN104910134A (zh) 2015-09-16
JP2010529964A (ja) 2010-09-02
CY1113178T1 (el) 2016-04-13
ES2391625T3 (es) 2012-11-28
AU2008262059A1 (en) 2008-12-18
US20140323495A1 (en) 2014-10-30
BRPI0812442A2 (pt) 2013-02-26
UY31125A1 (es) 2009-01-30
JP2013227324A (ja) 2013-11-07
EP2305263A1 (en) 2011-04-06
AR067328A1 (es) 2009-10-07
KR20120039717A (ko) 2012-04-25
CO6241118A2 (es) 2011-01-20
RU2009148985A (ru) 2011-08-20
CA2687741A1 (en) 2008-12-18
US20100178336A1 (en) 2010-07-15
US20130225598A1 (en) 2013-08-29
ZA200907961B (en) 2014-03-26
NZ598428A (en) 2013-06-28
RU2489149C2 (ru) 2013-08-10
JP5380440B2 (ja) 2014-01-08
KR20100020955A (ko) 2010-02-23
AU2008262059B2 (en) 2012-04-05
EP2000139A1 (en) 2008-12-10
NZ598427A (en) 2013-06-28
PT2305263E (pt) 2012-10-22
US20130022672A1 (en) 2013-01-24
HK1150764A1 (en) 2012-01-13
KR101267782B1 (ko) 2013-06-04
MY148878A (en) 2013-06-14

Similar Documents

Publication Publication Date Title
MX2009013272A (es) Formas amorfas estabilzadas de mesilato de imatinib.
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate
MY146403A (en) F, g, h, i and k crystal forms of imatinib mesylate
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
EA201400553A1 (ru) Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
PH12012502569A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
GB0524814D0 (en) Compounds
MY150098A (en) Benzylpiperazine derivates and their medical use
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
WO2009021965A3 (en) Substituted quinoline derivatives as h1 receptor antagonists
PT1853232E (pt) Forma cristalina estável de mesilato de bifeprunox, suas formas de dosagem e métodos para a sua utilização
PH12015501945B1 (en) Formulations of organic compounds
DE602007004327D1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors
ATE525370T1 (de) Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten
MY183976A (en) Pharmaceutical composition for oral administration with improved dissolution and/or absorption
UA93878C2 (ru) Производная бензилпиперазина, ee применение при лечении разных расстройств и фармацевтическая композиция, которая ee содержит
NZ624621A (en) Manufacturing process for pyrimidine derivatives
MX2009009572A (es) Sales de 3-(1h-indol-3-il)-4-[2-(4-metil-piperazin-i-il)-quinazoli n-4-il]-pirrole-2, 5-di ona.
TH121706B (th) รูปแบบอสัณฐานที่ถูกทำให้เสถียรของอิมาทินิบ มีซิเลท

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration